UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report:
(Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other Jurisdiction of Incorporation)
(Commission File Number) | (IRS Employer Identification No.) |
(Address of Principal Executive Offices and zip code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class | Trading Symbol(s) | Name of each Exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective December 8, 2022, Dr. Gregory Berk, President of Research & Development and Chief Medical Officer, is no longer employed by the Registrant.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GT BIOPHARMA, INC. | ||
Date: December 13, 2022 | By: | /s/ Manu Ohri |
Manu Ohri | ||
Chief Financial Officer |
Cover |
Dec. 08, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Dec. 08, 2022 |
Entity File Number | 1-40023 |
Entity Registrant Name | GT Biopharma, Inc. |
Entity Central Index Key | 0000109657 |
Entity Tax Identification Number | 94-1620407 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 8000 Marina Blvd. |
Entity Address, Address Line Two | Suite 100 |
Entity Address, City or Town | Brisbane |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94005 |
City Area Code | (800) |
Local Phone Number | 304-9888 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common stock, $0.001 par value |
Trading Symbol | GTBP |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
-8?20$3;8T.P6BP^0"X9
M9K>]9!:G
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end